Status:
TERMINATED
Preventing COVID-19 Complications With Low- and High-dose Anticoagulation
Lead Sponsor:
University Hospital, Geneva
Conditions:
COVID
Sars-CoV2
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The ongoing COVID-19 pandemic affects millions of humans worldwide and has led to thousands of acute medical hospitalizations. There is evidence that hospitalized cases often suffer from an important ...
Eligibility Criteria
Inclusion
- adult patient with COVID-19 infections, admitted to:
- an acute non-critical medical ward with admission D-dimer levels \>1,000ng/mL, or
- an acute critical ward (ICU, intermediate care unit)
Exclusion
- ongoing or planned therapeutic anticoagulation for any other indication
- contra-indication to therapeutic anticoagulation
- hypersensitivity to heparin
- personal history of heparin-induced thrombocytopenia
- suspected or confirmed bacterial endocarditis
- bleeding events or tendency due to a suspected or confirmed hemostatic bleeding disorder
- organic lesion prone to bleeding
- platelet count \<50G/L, Hb level \<80g/L
- ongoing or recent (\<30 days) major bleeding, ischemic stroke, trauma, surgery
- use of dual antiplatelet therapy
- pregnancy
- bodyweight \<40kg or \>150kg.
- end of life care setting
- unwillingness to consent
- ongoing participation in a COVID-19 randomized clinical trial testing another therapeutic intervention
Key Trial Info
Start Date :
April 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 2 2021
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT04345848
Start Date
April 28 2020
End Date
June 2 2021
Last Update
September 14 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Geneva University Hospitals
Geneva, Switzerland
2
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, Switzerland
3
Ospedale Regionale di Locarno
Locarno, Switzerland
4
Hôpital du Valais
Sion, Switzerland